- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04513912
Une étude sur le seltorexant par rapport à la quétiapine XR en tant que traitement d'appoint aux antidépresseurs chez des participants adultes et âgés atteints d'un trouble dépressif majeur avec des symptômes d'insomnie qui n'ont pas répondu de manière adéquate au traitement antidépresseur
Étude en double aveugle, randomisée, en groupes parallèles avec la quétiapine à libération prolongée comme comparateur pour évaluer l'efficacité et l'innocuité du seltorexant 20 mg en tant que traitement d'appoint aux antidépresseurs chez les patients adultes et âgés atteints d'un trouble dépressif majeur avec des symptômes d'insomnie qui n'ont pas répondu de manière adéquate au traitement antidépresseur
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Buenos Aires, Argentine, 1058AAJ
- CENydET - Centro Neurobiologico y de Stress Traumatico
-
Buenos Aires, Argentine, C1405BOA
- FunDaMos
-
Buenos Aires, Argentine, 1199
- Hospital Italiano
-
Ciudad Autonoma Buenos Aires, Argentine, C1428AQK
- Hospital Fleni
-
Córdoba, Argentine, X5004AOA
- Instituto Privado Kremer
-
Córdoba, Argentine, 5000
- Fundacion Lennox
-
Córdoba, Argentine, X5006IKK
- Centro Medico Luquez
-
La Plata, Argentine, Thanks
- Clinica Privada de Salud Mental Santa Teresa de Ávila
-
La Plata, Argentine, 1902
- CENPIA
-
Mendoza, Argentine, M5502AWY
- CENAIN
-
San Miguel de Tucumán, Argentine, 4000
- Clinica Mayo de UMCB
-
-
-
-
-
Bruges, Belgique, 8310
- AZ Sint-Lucas
-
Sint-Niklaas, Belgique, 9100
- AZ Nikolaas
-
-
-
-
-
Pleven, Bulgarie, 5800
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgarie, 4028
- MC 'Hipokrat - N', EOOD
-
Rousse, Bulgarie, 7003
- Mental Health Center - Rousse
-
Sofia, Bulgarie, 1680
- Medical Center Intermedica, OOD
-
Sofia, Bulgarie, 1113
- Medical Center St. Naum
-
Sofia, Bulgarie, 1784
- MC 'Synexus Sofia' EOOD
-
Stara Zagora, Bulgarie, 6003
- UMHAT Prof. Dr. St. Kirkovich AD
-
Stara Zagora, Bulgarie, 6000
- MC 'Synexus Sofia' EOOD
-
Tzarev Brod, Bulgarie, 9747
- State Psychiatric Hospital - Tzarev Brod
-
Varna, Bulgarie, 9020
- Diagnostic Consulting Center Mladost - M Varna
-
Veliko Tarnovo, Bulgarie, 5000
- Mental Health Center - Veliko Tarnovo EOOD
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1P 1E1
- A.K. Munshi Medical Inc.
-
-
Ontario
-
Toronto, Ontario, Canada, M3J 2C5
- Canadian Phase Onward
-
-
Quebec
-
Montreal, Quebec, Canada, H1M 1B1
- Clinique Force Medic (GCP Trials)
-
-
-
-
-
Jelgava, Lettonie, LV-3008
- The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
-
Liepāja, Lettonie, LV-3401
- L. Keruze Practice in Psychiatry
-
Outpatient Centre of Psychiatry, Lettonie, LV-4601
- Hospital of Rezekne
-
Riga, Lettonie, LV-1002
- Riga Centre of Psychiatry and Narcology
-
-
-
-
-
Kaunas, Lituanie, 48259
- Kaunas Silainiu Outpatient Clinic, Public Institution
-
Kaunas, Lituanie, 53136
- Republic Kaunas Hospital
-
Kaunas, Lituanie, LT-44279
- Romuvos Klinika, JSC
-
Kaunas, Lituanie, LT-50009
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics
-
Vilnius, Lituanie, 09112
- Zirmunai Mental Health Center, Public Institution
-
Vilnius, Lituanie, 10309
- Vilnius Mental Health Center
-
Vilnius, Lituanie, 10204
- Antakalnis Psychiatric Consultation Centre, Public Institution
-
Šilutė, Lituanie, 99176
- Medical Center Puriena JSC
-
-
-
-
-
Ipoh, Malaisie, 30990
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, Malaisie, 81200
- Hospital Permai
-
Pulau Pinang, Malaisie, 10990
- Hospital Pulau Pinang
-
Seremban, Malaisie, 70300
- Hospital Tuanku Jaafar
-
-
-
-
-
Bełchatów, Pologne, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bialystok, Pologne, 15-464
- Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
-
Bydgoszcz, Pologne, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, Pologne, 80 546
- Centrum Badan Klinicznych PI House sp z o o
-
Lodz, Pologne, 90-009
- Specjalistyczna Indywidualna Praktyka Lekarska
-
Lodz, Pologne, 90-368
- CCBR - Lodz - PL
-
Lublin, Pologne, 20-582
- Specjalistyczna Praktyka Lekarska Marek Domanski
-
Poznan, Pologne, 60-702
- Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
-
Warsaw, Pologne, 01 737
- Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
-
Warsaw, Pologne, 02 957
- Instytut Psychiatrii I Neurologii
-
-
-
-
-
Derby, Royaume-Uni, DE22 3LZ
- Kingsway Hospital
-
Greater Manchester, Royaume-Uni, M15 6SX
- Synexus
-
Harrogate, Royaume-Uni, HG1 2PW
- Garden Valleys Resource Centre
-
London, Royaume-Uni, SE5 8EF
- Kings College Hospital NHS Trust
-
Redruth, Royaume-Uni, TR15 2SP
- Cornwall Partnership Foundation Trust
-
-
-
-
-
Engel's, Russie, 413124
- Engels psychiatric hospital
-
Kemerovo, Russie, 650036
- Kemerovo Regional Clinical Psychiatric Hospital
-
Lipetsk Region, Russie, 399313
- GUZ Lipetsk Regional psychoneurological Hospital #1
-
Moscow, Russie, 105082
- JSC Scientific Centre of Personalized Medicine
-
Moscow, Russie, 107076
- FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
-
Moscow, Russie, 107076
- Moscow Scientific Research Institute of Psychiatry
-
Omsk, Russie, 644070
- Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
-
Saint Petersburg, Russie, 192019
- St-Petersburg Bekhterev Psychoneurological Research Institute
-
Tomsk, Russie, 634009
- Klinika StoLet Ltd
-
Yekaterinburg, Russie, 620030
- Sverdlov Regional Psychiatric Clinical Hospital
-
-
-
-
-
Belgrade, Serbie, 11000
- University Clinical Center of Serbia
-
Belgrade, Serbie, 11000
- General Hospital Euromedik
-
Belgrade, Serbie, 11000
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Belgrade, Serbie, 11000
- General Hospital Acibadem Bel Medic
-
Belgrade, Serbie, 11000
- Institute of Mental Health Serbia
-
Kovin, Serbie, 26220
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, Serbie, 34000
- University Clinical Center Kragujevac
-
Niš, Serbie, 18000
- Clinical Center Nis
-
Novi Kneževac, Serbie, 23330
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Banská Bystrica, Slovaquie, 97401
- Psychomed-Svatosavsky, s.r.o.
-
Bojnice, Slovaquie, 97201
- Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
-
Košice, Slovaquie, 040 11
- Epamed sro
-
Liptovský Mikuláš, Slovaquie, 03123
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Slovaquie, 97901
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Trenčín, Slovaquie, 91101
- FN Trencin
-
Trenčín, Slovaquie, 91108
- Pro mente sana s.r.o.
-
Žilina, Slovaquie, 1207
- Fakultna nemocnica s poliklinikou v Ziline
-
-
-
-
-
Brno, Tchéquie, 60200
- Psychiatricka ambulance Saint Anne s.r.o.
-
Hradec Králové, Tchéquie, 500 09
- NeuropsychiatrieHK, s.r.o.
-
Pilsen, Tchéquie, 301 00
- A Shine S R O
-
Prague, Tchéquie, 100 00
- Clintrial s r o
-
Prague, Tchéquie, 160 00
- NeuropsychiatrieHK, s.r.o.
-
Prague, Tchéquie, 10000
- AD71 s.r.o.
-
Prague, Tchéquie, 186 00
- Institut Neuropsychiatricke pece
-
-
-
-
-
Hlevakha, Ukraine, 8631
- MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
-
Kharkiv, Ukraine, 61068
- Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
-
Kyiv, Ukraine, 04080
- Kyiv Territorial Medical Incorporation 'Psychiatry'
-
Kyiv, Ukraine, 1030
- Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
-
Kyiv, Ukraine, 1034
- Medical Center Health and Happy
-
Nove, Ukraine, 25491
- Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
-
Ternopil, Ukraine, 46020
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
-
Zaporizhzhya, Ukraine, 69600
- Zaporizhzhia Regional Clinical Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85712
- SW Biomedical Research LLC
-
-
California
-
Culver City, California, États-Unis, 90230
- Proscience Research Group
-
Encino, California, États-Unis, 91316
- Pharmacology Research Institute
-
Garden Grove, California, États-Unis, 92845
- Collaborative NeuroScience Network
-
Long Beach, California, États-Unis, 90806
- Collaborative NeuroScience Network
-
Los Alamitos, California, États-Unis, 90720
- Pharmacology Research Institute
-
Los Angeles, California, États-Unis, 90025
- CalNeuro Research
-
Newport Beach, California, États-Unis, 92660
- Pharmacology Research Institute
-
Orange, California, États-Unis, 92868
- NRC Research Institute
-
Orange, California, États-Unis, 92868
- Pacific Neuropsychiatric Specialists
-
Pico Rivera, California, États-Unis, 90660
- CNRI-Los Angeles, LLC
-
Rancho Cucamonga, California, États-Unis, 91730
- Prospective Research Innovations Inc
-
Redlands, California, États-Unis, 92374
- Anderson Clinical Research
-
San Diego, California, États-Unis, 92103
- University of California at San Diego
-
Santa Ana, California, États-Unis, 92705
- CI Trials
-
Santa Ana, California, États-Unis, 91704
- National Research Institute
-
Santee, California, États-Unis, 92071
- CMB Clinical Trials
-
Sherman Oaks, California, États-Unis, 91403
- Schuster Medical Research Institute
-
Upland, California, États-Unis, 91786
- Pacific Clinical Research Medical Group
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06102
- Hartford Hospital
-
-
Florida
-
Doral, Florida, États-Unis, 33166
- Moonshine Research Center, Inc
-
Hallandale, Florida, États-Unis, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, États-Unis, 33012
- Indago Research & Health Center Inc
-
Hialeah, Florida, États-Unis, 33012
- New Life Medical Research Center, Inc.
-
Hialeah, Florida, États-Unis, 33013
- Amedica Research Institute Inc
-
Lakeland, Florida, États-Unis, 33803
- Meridien Research
-
Miami, Florida, États-Unis, 33122
- Premier Clinical Research
-
Miami, Florida, États-Unis, 33125
- Global Medical Institutes
-
Miami, Florida, États-Unis, 33137
- Miami Jewish Health System
-
Orlando, Florida, États-Unis, 32806
- Synexus Research Orlando
-
Orlando, Florida, États-Unis, 23801
- Clinical Neuroscience Solutions
-
Tampa, Florida, États-Unis, 33612
- University of South Florida
-
The Villages, Florida, États-Unis, 32162
- Compass Research LLC-Bioclinica Research
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30331
- Atlanta Center for Medical Research
-
Atlanta, Georgia, États-Unis, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, États-Unis, 30030
- iResearch Atlanta LLC
-
Marietta, Georgia, États-Unis, 30060
- Psych Atlanta, P.C.
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60634
- Chicago Research Center
-
Libertyville, Illinois, États-Unis, 60048
- Capstone Clinical Research
-
Lisle, Illinois, États-Unis, 60532
- Alexian Brothers Health System
-
Naperville, Illinois, États-Unis, 60563
- Baber Research Group
-
Oakbrook Terrace, Illinois, États-Unis, 60618
- Lemah Creek Clinical Research
-
-
Kansas
-
Wichita, Kansas, États-Unis, 67214
- Ascension via Christi Research
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70115
- Riverstar Research
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21208
- Pharmasite Research, Inc.
-
-
Massachusetts
-
New Bedford, Massachusetts, États-Unis, 02740
- BTC of New Bedford
-
Roslindale, Massachusetts, États-Unis, 02135
- Boston Clinical Trials & Medical Research
-
-
Missouri
-
O'Fallon, Missouri, États-Unis, 63368
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, États-Unis, 08755
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, États-Unis, 11235
- SPRI Clinical Trials, LLC
-
New York, New York, États-Unis, 10128
- The Medical Research Network, LLC
-
New York, New York, États-Unis, 10017
- Fieve Clinical Research Inc
-
Rochester, New York, États-Unis, 14618 1609
- Finger Lakes Clinical Research
-
Staten Island, New York, États-Unis, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27701
- Velocity Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
-
Dayton, Ohio, États-Unis, 45417
- Midwest Clinical Research Center
-
North Canton, Ohio, États-Unis, 44720
- Neuro Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73112
- Sooner Clinical Research
-
Oklahoma City, Oklahoma, États-Unis, 73118
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Pine Hill, Pennsylvania, États-Unis, 08021
- Suburban Research Associates
-
Scranton, Pennsylvania, États-Unis, 18503
- Global Medical Institutes
-
-
South Carolina
-
Mt. Pleasant, South Carolina, États-Unis, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Bellaire, Texas, États-Unis, 77401
- West Houston Clinical Research Service
-
Fort Worth, Texas, États-Unis, 76104
- North Texas Clinical Trials
-
Mansfield, Texas, États-Unis, 76054
- Hawkins Psychiatry, PC
-
The Woodlands, Texas, États-Unis, 77381
- Family Psychiatry of The Woodlands
-
Wichita Falls, Texas, États-Unis, 76309
- Grayline Research Center
-
-
Utah
-
Clinton, Utah, États-Unis, 84015
- Alpine Research Organization
-
Draper, Utah, États-Unis, 84020
- Cedar Clinical Research
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- University of Virginia
-
-
Washington
-
Bellevue, Washington, États-Unis, 98007
- Northwest Clinical Research Center
-
Everett, Washington, États-Unis, 98201
- Core Clinical Research
-
-
Wisconsin
-
Waukesha, Wisconsin, États-Unis, 53188
- Cary J. Kohlenberg, MD, SC, dba, IPC Research.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Seltorexant
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182. |
Participants will receive seltorexant over-encapsulated tablet orally. Participants will receive placebo over-encapsulated tablet matching to seltorexant orally. |
|
Comparateur actif: Quetiapine Extended-Release (XR)
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability. |
Participants will receive quetiapine XR capsule orally. Participants will receive placebo capsule matching to quetiapine XR orally. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Délai: Week 26
|
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline to Week 26 in Weight
Délai: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in weight was reported. |
Baseline (Day 1) and Week 26
|
|
Time to Potentially Treatment Related Discontinuation of Study Drug
Délai: From first dose of study drug (Day 1) up to Week 30
|
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used. |
From first dose of study drug (Day 1) up to Week 30
|
|
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Délai: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in MADRS-6 Total Score
Délai: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Délai: Baseline (Day 1) and Week 26
|
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Délai: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Délai: Week 26
|
Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Délai: Week 26
|
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Délai: Week 26
|
Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported. |
Week 26
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CR108810
- 42847922MDD3005 (Autre identifiant: Janssen Research & Development, LLC)
- 2020-000341-14 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .